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r c c  remains to be delineated. Ideally, clinicians will 
be able to identify high-risk patients and offer treat-
ment to those who would benefit most from adjuvant 
and neoadjuvant therapy, while minimizing toxicity 
in low-risk patients.
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1.  INTRODUCTION
With more than 54,000 new cases and an estimated 
13,000 deaths in the United States in 2008, renal 
cell carcinoma (r c c ) shows a mortality rate that 
has declined slightly since 1990, but that continues 
to inflict a large burden of disease 1. Nephrectomy 
provides curative treatment for localized disease, but 
unfortunately, 30% of patients subsequently experi-
ence recurrence and metastasis, with survival rates 
below 10% 2. With accurate preoperative risk strati-
fication, patients at high risk can be identified and 
offered neoadjuvant or adjuvant therapy for optimal 
management. The advent of small-molecule targeting 
agents such as sunitinib, sorafenib, and temsirolimus 
provides an avenue for such therapy in this patient 
population. We address such treatments here, and 
also discuss a pilot study currently under way at our 
centre to investigate neoadjuvant temsirolimus for 
high-risk r c c .
2.  APPROACH TO NEOADJUVANT OR 
ADJUVANT THERAPY
2.1	 Defining	Risk
Although a complete discussion of the current status 
of risk stratification and prognostication in r c c  is 
beyond the scope of this review, an accurate defini-
tion of risk in patients with r c c  is imperative in de-
termining those most likely to benefit from adjuvant 
and neoadjuvant therapy and in reducing toxicity in 
low-risk patients. We recommend a recent review by 
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Non-localized renal cell carcinoma (r c c ) carries a 
poor prognosis with a significant risk of mortality for 
patients. Traditionally, interleukin-2 and interferon 
alfa have been administered in this setting, with high 
toxicity and limited improvement in cancer-specific 
survival. However, newer agents such as sunitinib, 
sorafenib, bevacizumab, and temsirolimus have dem-
onstrated great potential and provide a new frontier 
in the management of high-risk r c c .
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the keywords “renal cell carcinoma,” “high risk” and 
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from these searches and the reference lists of relevant 
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1996 and 2008 were included in the present review.
Results
Risk stratification is imperative for optimal patient 
selection in adjuvant, neoadjuvant, and research set-
tings. Utilization of interferon alfa and interleukin-2 
has not demonstrated improved disease-free survival 
in the adjuvant setting. A number of adjuvant vaccines 
have also failed to demonstrate improved survival. 
The adjuvant role of targeted small-molecule inhibi-
tors such as sorafenib, sunitinib, and temsirolimus 
is currently under investigation in phase iii trials. 
Sporadic case reports have demonstrated promising 
results with neoadjuvant use of these agents, and a 
pilot study of neoadjuvant temsirolimus is currently 
underway at our centre.
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Downs et al. 3 for a more comprehensive discussion 
of this important and rapidly evolving topic of risk 
assessment in r c c .
Currently, tumour stage continues to be the most 
important prognostic factor for patients with r c c. 
This understanding has been validated in a study 
of 2746 patients followed for a median of 9 years: 
5-year cancer-specific survival rates by stage were 
97% (pT1a), 87% (pT1b), 71% (pT2), 53% (pT3a), 
44% (pT3b), 37% (pT3c), and 20% (pT4), using the 
2002 American Joint Committee on Cancer tumour 
classification system 4. Within the current pT3 clas-
sification, the level of inferior vena cava involvement 
or the type of tissue invaded has failed to be associated 
with a significant difference in survival, and Terrone 
et al. further classified pT3 tumours by defining those 
invading either the perirenal or sinus fat to signifi-
cantly constitute the lowest mortality risk 5.
In addition to tumour stage, other parameters such 
as age, performance status, constitutional symptoms, 
number of metastatic sites, site of metastasis, sar-
comatoid histology, papillary r c c  type 2 histology, 
Fuhrman grade, microvascular tumour invasion, 
neutrophil count, serum lactate dehydrogenase level, 
serum C-reactive protein level, thyroid-stimulating 
hormone level, plasma adiponectin, oncofetal protein 
Imp3 (insulin-like growth factor ii mr n a -binding 
protein 3), vascular endothelial growth factor (v e g f ), 
carbonic anhydrase ix, intratumoral polyamines, 
erythropoietin, B7-H1, and Ki-67 have illustrated 
prognostic and stratification utility in various stud-
ies 2,6–17. Further studies are required with larger 
patient numbers and longer duration of follow-up 
to delineate the role of these variables in the natural 
history of r c c, to identify limitations, and to establish 
external validation of findings.
Recently devised integrated stratification systems 
attribute a value to various clinical and histologic 
features, and these combinations permit risk assess-
ment within a defined patient population. The two 
most extensively studied integrated stratification 
systems for r c c  are the Mayo Clinic stage, size, grade 
and necrosis (s s i g n) score for clear-cell r c c  (ccr c c ) 
and the University of California–Los Angeles (u c l a ) 
integrated staging system (u i s s ) for r c c  18,19. The s s i g n 
scoring algorithm was devised following an analysis 
of 1801 patients with unilateral ccr c c . The analysis 
revealed that the 1997 TNM staging system, tumour 
size greater than 5 cm, nuclear grade, and histologic 
necrosis are predictive of cancer-specific mortality 18. 
Patients with s s i g n scores of 0–2, 3–4, 5–6, and 7–9 
have 5-year cancer-specific survival rates of 100%, 
91%, 64%, and 47% respectively; all patients scoring 
10 or more die of their disease within 2 years 3.
The u i s s system uses a combination of 1997 TNM 
stage, Fuhrman grade, and Eastern Cooperative On-
cology Group performance status (e c o g -p s) that was 
identified by Zisman et al., through an analysis of 661 
patients at u c l a , as significantly predictive of cancer-
specific survival 19. Initially, this method identified 
5 statistically significant categories that stratified 
metastatic and nonmetastatic patients together, with 
5-year survival in u i s s categories i, ii, iii, iv, and v 
being 94%, 67%, 39%, 23%, and 0% respectively 19. 
These 5 categories were later incorporated into either 
metastatic or nonmetastatic low-risk, intermediate-
risk, and high-risk stratifications, providing a prac-
tical means of assessing risk in patients with r c c  
not unlike the system used in prostate cancer 20. 
Reported 5-year disease-specific survival for low-, 
intermediate-, and high-risk nonmetastatic patients 
are 91%, 80%, and 54%; for metastatic patients, the 
corresponding rates are 32%, 20%, and 0%. To assign 
risk categories, decision boxes have been created for 
metastatic and nonmetastatic patients, in which risk 
is defined by progression downward from stage to 
grade to e c o g -p s. In addition, analysis of freedom 
from recurrence in nonmetastatic patients revealed 
that 91% of low-risk, 64% of intermediate-risk, and 
37% of high-risk patients are free from any recur-
rence at 5 years. Given these statistically significant 
differences in recurrence, and a tendency for low-risk 
patients to recur in the chest (high-risk patients recur 
in the abdomen), various postoperative surveillance 
regimens have been defined 21,22.
Both of these integrative models have been exter-
nally validated: the u i s s  with at least 8249 patients, 
and the s s i g n with 2656 patients 23–26. Regarding pre-
dictive capacity, the s s i g n score appears to be slightly 
superior to the u i s s  in nonmetastatic patients, having 
shown a predictive accuracy of 0.830 as compared 
with 0.760 in one study of 388 patients. However, the 
authors of the latter study did not report whether the 
difference was statistically significant, and clinical 
significance has yet to be established 27. Neverthe-
less, recent findings indicate that the addition of 5 
molecular markers to the u i s s  increases its predictive 
accuracy to 0.903 27. The u i s s  system is currently 
limited by the complexity and technical demands 
of obtaining molecular markers from all patients. A 
potential limitation of the s s i g n system is its reliance 
on histologic tumour necrosis, which does not have 
a standardized definition, consensus for reporting, 
or availability at many centres 27. Lastly, it should 
be noted that the s s i g n is applicable only to patients 
with ccr c c  (Table i).
Nomograms have also been developed to elu-
cidate the prognosis of patients with r c c ; however, 
although these tools are useful for individuals, they 
do not stratify patients into risk groups, thus limiting 
their role in clinical trial design and implementation 
of adjuvant and neoadjuvant therapy 28–31.
2.2	 Adjuvant	Therapy
Much effort has been invested toward the development 
of an effective and pragmatic strategy for adjuvant 
treatment of r c c . The use of radiation therapy was KAPOOR et al.
Cu r r e n t On C O l O g y —VO l u m e  16, Su p p l e m e n t 1
S62
t
a
b
l
e
 
i
 
 
C
o
m
p
a
r
i
s
o
n
 
o
f
 
t
h
e
 
c
l
i
n
i
c
a
l
 
s
t
a
g
e
,
 
s
i
z
e
,
 
g
r
a
d
e
,
 
a
n
d
 
n
e
c
r
o
s
i
s
 
(
s
s
i
g
n
)
 
s
c
o
r
e
 
a
n
d
 
t
h
e
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
C
a
l
i
f
o
r
n
i
a
–
L
o
s
 
A
n
g
e
l
e
s
 
i
n
t
e
g
r
a
t
e
d
 
s
t
a
g
i
n
g
 
s
y
s
t
e
m
 
(
u
i
s
s
)
 
i
n
t
e
g
r
a
t
e
d
 
m
o
d
e
l
s
 
o
f
 
r
i
s
k
 
s
t
r
a
t
i
fi
c
a
t
i
o
n
M
o
d
e
l
 
 
P
a
r
a
m
e
t
e
r
s
 
 
H
i
s
t
o
l
o
g
y
 
 
E
x
t
e
r
n
a
l
 
 
P
a
t
i
e
n
t
s
 
 
L
i
m
i
t
a
t
i
o
n
s
 
 
 
 
 
 
 
v
a
l
i
d
a
t
i
o
n
 
 
(
n
)
 
s
s
i
g
n
 
t
n
M
 
s
t
a
g
e
,
 
s
i
z
e
,
 
c
c
r
c
c
 
Y
e
s
 
2
6
5
6
 
R
e
l
i
a
n
c
e
 
u
p
o
n
 
s
u
b
j
e
c
t
i
v
e
 
g
r
a
d
e
,
 
n
e
c
r
o
s
i
s
 
 
 
 
v
a
r
i
a
b
l
e
 
o
f
 
n
e
c
r
o
s
i
s
u
i
s
s
 
e
c
o
g
-
p
s
,
 
F
u
h
r
m
a
n
 
g
r
a
d
e
,
 
r
c
c
 
Y
e
s
 
8
2
4
9
 
R
e
d
u
c
e
d
 
p
r
e
d
i
c
t
i
v
e
 
p
o
w
e
r
 
T
N
M
 
s
t
a
g
e
 
 
 
 
i
n
 
n
o
n
m
e
t
a
s
t
a
t
i
c
 
p
a
t
i
e
n
t
s
T
M
N
 
=
 
t
u
m
o
u
r
 
s
i
z
e
,
 
m
e
t
a
s
t
a
s
i
s
,
 
a
n
d
 
n
o
d
a
l
 
i
n
v
o
l
v
e
m
e
n
t
 
s
t
a
g
i
n
g
 
s
y
s
t
e
m
;
 
c
c
r
c
c
 
=
 
c
l
e
a
r
-
c
e
l
l
 
r
e
n
a
l
 
c
e
l
l
 
c
a
r
c
i
n
o
m
a
;
 
e
c
o
g
-
p
s
 
=
 
E
a
s
t
e
r
n
 
C
o
o
p
e
r
a
t
i
v
e
 
O
n
c
o
l
o
g
y
 
G
r
o
u
p
 
p
e
r
f
o
r
m
a
n
c
e
 
s
t
a
t
u
s
;
 
r
c
c
 
=
 
r
e
n
a
l
 
c
e
l
l
 
c
a
r
c
i
n
o
m
a
.
t
a
b
l
e
 
i
i
 
 
O
n
g
o
i
n
g
 
a
d
j
u
v
a
n
t
 
t
h
e
r
a
p
y
 
t
r
i
a
l
s
 
f
o
r
 
h
i
g
h
-
r
i
s
k
 
r
e
n
a
l
 
c
e
l
l
 
c
a
r
c
i
n
o
m
a
 
(
r
c
c
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
r
i
a
l
 
n
a
m
e
 
 
P
r
i
n
c
i
p
a
l
 
 
E
s
t
i
m
a
t
e
d
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
r
e
a
t
m
e
n
t
 
a
r
m
s
 
 
P
r
i
m
a
r
y
 
 
E
s
t
i
m
a
t
e
d
 
 
 
i
n
v
e
s
t
i
g
a
t
o
r
 
 
a
c
c
r
u
a
l
 
 
 
 
o
u
t
c
o
m
e
 
 
d
a
t
e
 
o
f
 
 
 
 
 
(
n
)
 
 
 
 
 
 
c
o
m
p
l
e
t
i
o
n
 
a
s
s
u
r
e
 
N
.
S
.
 
B
l
a
z
e
r
–
H
a
a
s
,
 
e
t
 
a
l
.
 
1
3
3
2
 
S
u
n
i
t
i
n
i
b
:
 
o
r
a
l
l
y
 
e
v
e
r
y
 
o
t
h
e
r
 
d
a
y
;
 
D
i
s
e
a
s
e
-
 
A
p
r
 
2
0
1
6
 
 
 
(
A
d
j
u
v
a
n
t
 
S
o
r
a
f
e
n
i
b
 
o
r
 
S
u
n
i
t
i
n
i
b
 
N
a
t
i
o
n
a
l
 
C
a
n
c
e
r
 
I
n
s
t
i
t
u
t
e
 
 
 
 
 
4
 
w
e
e
k
s
 
o
n
,
 
2
 
w
e
e
k
s
 
r
e
s
t
,
 
a
n
d
 
6
 
w
e
e
k
s
 
p
l
a
c
e
b
o
 
s
o
r
a
f
e
n
i
b
;
 
f
r
e
e
 
 
 
f
o
r
 
U
n
f
a
v
o
r
a
b
l
e
 
R
e
n
a
l
 
C
a
r
c
i
n
o
m
a
)
 
 
 
v
s
.
 
s
o
r
a
f
e
n
i
b
:
 
o
r
a
l
l
y
 
t
w
i
c
e
 
d
a
i
l
y
;
 
 
s
u
r
v
i
v
a
l
 
 
 
 
 
 
6
 
w
e
e
k
s
 
o
n
,
 
4
 
w
e
e
k
s
 
p
l
a
c
e
b
o
 
s
u
n
i
t
i
n
i
b
,
 
a
n
d
 
2
 
w
e
e
k
s
 
r
e
s
t
;
 
 
 
v
s
.
 
p
l
a
c
e
b
o
s
o
r
c
e
 
T
.
 
E
i
s
e
n
,
 
1
6
5
6
 
S
o
r
a
f
e
n
i
b
:
 
o
r
a
l
l
y
 
t
w
i
c
e
 
d
a
i
l
y
;
 
1
 
y
e
a
r
 
o
n
 
a
n
d
 
2
 
y
e
a
r
s
’
 
p
l
a
c
e
b
o
;
 
D
i
s
e
a
s
e
-
 
A
u
g
 
2
0
1
2
 
 
 
(
P
h
a
s
e
 
i
i
i
 
R
a
n
d
o
m
i
z
e
d
 
D
o
u
b
l
e
-
b
l
i
n
d
 
S
t
u
d
y
 
C
a
n
c
e
r
 
R
e
s
e
a
r
c
h
 
U
K
 
 
v
s
.
 
s
o
r
a
f
e
n
i
b
:
 
o
r
a
l
l
y
 
t
w
i
c
e
 
d
a
i
l
y
;
 
3
 
y
e
a
r
s
 
o
n
;
 
f
r
e
e
 
 
 
C
o
m
p
a
r
i
n
g
 
S
o
r
a
f
e
n
i
b
 
w
i
t
h
 
P
l
a
c
e
b
o
 
a
t
 
C
a
m
b
r
i
d
g
e
 
 
v
s
.
 
p
l
a
c
e
b
o
 
s
u
r
v
i
v
a
l
 
 
 
i
n
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
R
e
s
e
c
t
e
d
 
P
r
i
m
a
r
y
 
r
c
c
 
R
e
s
e
a
r
c
h
 
I
n
s
t
i
t
u
t
e
 
 
 
a
t
 
H
i
g
h
 
o
r
 
I
n
t
e
r
m
e
d
i
a
t
e
 
R
i
s
k
 
o
f
 
R
e
l
a
p
s
e
)
s
-
t
r
a
c
 
P
fi
z
e
r
 
I
n
c
.
 
2
9
0
 
S
u
n
i
t
i
n
i
b
:
 
o
r
a
l
l
y
 
e
v
e
r
y
 
o
t
h
e
r
 
d
a
y
;
 
 
D
i
s
e
a
s
e
-
 
S
e
p
 
2
0
1
1
 
 
 
(
S
u
n
i
t
i
n
i
b
 
T
r
e
a
t
m
e
n
t
 
 
 
 
 
 
4
 
w
e
e
k
s
 
o
n
,
 
2
 
w
e
e
k
s
 
r
e
s
t
,
 
a
n
d
 
6
 
w
e
e
k
s
 
p
l
a
c
e
b
o
 
s
o
r
a
f
e
n
i
b
;
 
f
r
e
e
 
 
 
o
f
 
R
e
n
a
l
 
A
d
j
u
v
a
n
t
 
C
a
n
c
e
r
)
 
 
 
v
s
.
 
s
o
r
a
f
e
n
i
b
:
 
o
r
a
l
l
y
 
t
w
i
c
e
 
d
a
i
l
y
;
 
 
s
u
r
v
i
v
a
l
 
 
 
 
 
 
6
 
w
e
e
k
s
 
o
n
,
 
4
 
w
e
e
k
s
 
p
l
a
c
e
b
o
 
s
u
n
i
t
i
n
i
b
,
 
a
n
d
 
2
 
w
e
e
k
s
 
r
e
s
t
)
 
 
 
v
s
.
 
p
l
a
c
e
b
oREVIEW OF THERAPY IN HIGH-RISK RCC
S63
Cu r r e n t On C O l O g y —VO l u m e  16, Su p p l e m e n t 1
investigated in this light and found to be equivalent to 
observation in terms of relapse rate and survival 32,33. 
Furthermore, this modality expressed significant mor-
bidity and mortality with a 44% complication rate 32. 
Currently, radiation therapy in the adjuvant setting has 
been abandoned and is being used only for palliation 
of symptomatic bone metastases.
The use of hormonal therapy has also been ex-
plored as a potential for adjuvant treatment of high-
risk r c c . In a prospective randomized study of 136 
patients, medroxyprogesterone acetate was found to 
provide no benefit with regard to disease recurrence 
and was associated with significant toxicity 34.
Immunotherapy has been another area of active 
investigation as an adjuvant strategy in r c c . A mod-
est benefit in survival was reported with interferon 
alfa (i f nα) and with interleukin-2 (il-2) therapy in 
the context of metastatic r c c, but these immune 
modulators do not currently have a defined role in 
the adjuvant setting. In randomized trials, adjuvant 
i f nα and the widely available recombinant i f nα2b 
have been shown not to contribute to survival or 
relapse-free survival 35,36. For example, a phase iii trial 
investigating adjuvant il-2 in high-dose bolus form 
was closed early because an interim analysis revealed 
that disease-free survival was not affected 37. A sub-
sequent study investigating adjuvant il-2 in low-dose 
subcutaneous form was also ineffective with respect 
to disease-free survival 38.
A more passive method of immunomodulation 
and its application to adjuvant therapy in r c c has 
come in the form of tumour vaccines. Galligioni et al. 
investigated the use of autologous irradiated tumour 
cells mixed with bacillus Calmette–Guèrin as an ad-
juvant strategy and found no statistically significant 
improvement in overall or disease-free survival 39, but 
a multicentre phase iii randomized controlled trial of 
adjuvant autologous tumour-cell vaccine conducted 
in Germany show a statistically significant disease-
free survival benefit 40. In the latter investigation, 
379 patients with pT2–3b pN0–3 M0 disease were 
included in the analysis, and 5-year progression-free 
survival was 77.4% and 67.8% in the vaccine and 
the control groups respectively. That study has been 
widely criticized because 174 patients were lost to 
follow-up after randomization and also because dif-
ferences in overall survival were not analyzed.
Another vaccine strategy has focused on the use 
of heat shock proteins. The heat shock protein peptide 
complex HSPPC-96 (vitespen) was developed from 
autologous tumours in r c c. Following encouraging re-
sults in a phase ii trial, a 728-patient multicentre open-
label randomized phase iii trial compared adjuvant 
HSPPC-96 with observation following nephrectomy 
and found no difference in recurrence-free survival 
after a median follow-up of 1.9 years 41.
The use of monoclonal antibodies has also been 
considered in the adjuvant treatment of r c c . Recently, 
an immunoglobulin G1 antibody known as cG250 
(WX-G250) was found to bind carbonic anhydrase ix, 
which is a r c c -specific tumour antigen. A phase iii 
trial investigating the use of cG250 as compared with 
placebo following nephrectomy [the a r i s e r  (Adjuvant 
Rencarex Immunotherapy Trial to Study Efficacy in 
Nonmetastasized RCC) study] is currently in prog-
ress, with results expected in 2013 42.
A new frontier in the adjuvant treatment of r c c has 
focused on the use of small-molecule kinase inhibi-
tors and anti-vascular agents. Although no substantial 
studies have yet justified the use of these agents in 
the adjuvant setting, sorafenib 43, sunitinib 44, and 
temsirolimus 45 have been established as appropriate 
treatment options in metastatic r c c . These agents are 
thought to work through a mechanism influencing the 
involvement of the tumor-suppressor VHL gene in the 
pathogenesis of r c c . Spontaneous inactivation of VHL 
in sporadic cases of r c c  results in the overexpression 
of v e g f s, platelet-derived growth factors (p d g f s) 
and hypoxia-inducible factors (h i f s) 44. Sorafenib 
and sunitinib reduce tumour-cell proliferation and 
angiogenesis by acting as small-molecule inhibitors 
of multiple kinases; v e g f  receptors 1, 2, and 3; p d g f  
beta receptors; and f M s -like tyrosine kinase 3 (Flt3), 
among others 46. Temsirolimus is a mammalian target 
of rapamycin kinase inhibitor and antagonizes cell 
growth and proliferation by disrupting intracellular 
signalling pathways. Furthermore, temsirolimus 
blocks h i f a , which drives the downstream regulation 
of a number of pro-angiogenic factors 45.
Given the favourable effect of these agents in the 
treatment of metastatic r c c , several trials are now 
underway to evaluate their use as adjuvant therapies 
in high-risk surgically resectable r c c (Table ii). The 
a s s u r e  trial is a multicentre double-blind randomized 
study examining 1332 patients who underwent neph-
rectomy for pT1b, G3–4; pT2–pT4; or any T stage 
with node-positive disease. Patients will be stratified 
into intermediate high-risk or very high-risk groups 
and then randomized for 1 year of oral sorafenib, suni-
tinib, or placebo. Very high-risk patients are those with 
grades 3–4 pT3a, any pT3a with adrenal involvement, 
or pT3b–4 and any N+. Intermediate high-risk patients 
are those with grades 3–4 pT1b, any pT2, or grades 1–2 
pT3a without adrenal involvement. In addition to 
disease-free and overall survival, the study will inves-
tigate biomarkers, genetic mutations, d n a  methylation, 
and genetic polymorphisms as predictors of survival 
and therapeutic benefit. The investigation commenced 
in May 2006, and the estimated date of completion is 
April 2016. (For details, search for “NCT00326898” 
at www.clinicaltrials.gov/ct2/search)
Another ongoing adjuvant trial called the s o r c e  
trial is a multicentre double-blind randomized study 
with an estimated enrolment of 1656 patients with 
resected primary r c c  at high- or intermediate-risk of 
relapse (defined by investigators as a Leibovich score 
of 3–11). Patients are to be randomized to receive 
either sorafenib for 1 year, sorafenib for 3 years, or KAPOOR et al.
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placebo. The primary outcome measure is disease-free 
survival; secondary outcome measures are metastasis-
free survival, overall survival, cost effectiveness, and 
toxicity. The s o r c e  trial opened recruitment in June 
2007 and is estimated to be completed by August 
2012. (For details, search for “NCT00492258” at 
www.clinicaltrials.gov/ct2/search)
A third trial known as s-t r a c  addresses the use of 
adjuvant sunitinib. With a multicentre double-blind 
randomized design, this study will compare 1 year 
of oral sunitinib with placebo in 290 patients at high 
risk of recurrence (based on u i s s  criteria) following 
nephrectomy. The primary endpoint of the study 
is disease-free survival, and secondary endpoints 
to be assessed will be overall survival, safety, and 
patient-recorded outcomes. The projected timeline 
for this investigation is July 2007 to March 2011 47. 
(For details, search for “NCT00375674” at www.
clinicaltrials.gov/ct2/search)
2.3	 Neoadjuvant	Therapy
A review of the current literature failed to reveal any 
prospective studies in the field of neoadjuvant therapy 
for high-risk r c c . Until recently, cytokine-based immu-
notherapy had been the mainstay of systemic therapy 
in r c c, but its significant toxicity and poor primary 
tumour response are believed to have limited any inves-
tigations in the neoadjuvant setting 47. However, with 
the advent and subsequent success of small-molecule 
inhibitors for advanced r c c  39–41, the prospect of their 
application in a neoadjuvant strategy is provocative 
and exciting. Certainly, the theoretical benefits are 
intriguing and include tumour downstaging, reduc-
tion in pro-angiogenic factors, and possible response 
in the primary tumour. Several centres have published 
stimulating case reports demonstrating that neoadju-
vant treatment with various permutations of sorafenib, 
sunitinib, and bevacizumab resulted in a reduction of 
primary tumour size 47–49, tumour thrombus 47,49, bulky 
lymphadenopathy 47,48, and metastatic lesions 47.
3.  MCMASTER UNIVERSITY EXPERIENCE
Currently, there is a paucity of knowledge on the 
biologic response of r c c  to small-molecule inhibitors 
in vivo. This, along with the exciting potential of the 
application of these agents in the neoadjuvant setting 
of high-risk r c c  patients, has compelled our centre to 
undertake a nonrandomized open-label outpatient 
pilot study investigating the use of temsirolimus 
before nephrectomy in patients with high-risk and 
metastatic r c c . Patients receive 25 mg temsirolimus 
by intravenous infusion on a weekly basis for 12 
weeks before nephrectomy. Patients with metastatic 
disease continue to receive the same dose postopera-
tively for a maximum of 24 months, or until disease 
progression. A renal-mass biopsy and biomarker 
analysis is performed upon entry into the study. 
Efficacy will be evaluated using the Response Eval-
uation Criteria in Solid Tumors, and safety will be 
evaluated using the National Cancer Institute Com-
mon Toxicity Criteria for Adverse Events. The ap-
proximate duration of this study is 5 years, with an 
estimated enrolment of 20 subjects.
To date, 5 patients have been enrolled in the trial. 
Three patients have undergone uneventful laparo-
scopic radical nephrectomy. Patient 1 (10-cm renal 
mass with bulky adenopathy T2N2M0) is n e d  (no 
evidence of disease) at 6 months post-nephrectomy. 
Patient 2 (9-cm renal mass, bulky adenopathy, pul-
monary metastases T2N2M1) is n e d  at 3 months 
post-nephrectomy. Patient 3 (7-cm renal mass, pul-
monary metastases, T2N0M1) has recently undergone 
uneventful surgery, and follow-up computed tomogra-
phy is pending. Patients 4 and 5 are receiving weekly 
temsirolimus, and surgery is planned.
These preliminary and early results suggest that 
neoadjuvant temsirolimus before radical nephrectomy 
for advanced r c c  may induce disease regression 
post-surgery, and may even lead to disease resolution 
in patients with low-volume disease. Longer term 
follow-up is necessary to assess overall progression-
free survival and overall survival.
4.  CONCLUSIONS
In summary, the role, efficacy, and toxicity of adjuvant 
and neoadjuvant targeted small-molecule inhibitors in 
high-risk r c c  remain to be delineated. Ideally, clini-
cians will be able to identify high-risk patients and to 
offer treatment to those who would benefit most from 
adjuvant and neoadjuvant therapy, while minimizing 
toxicity in low-risk patients.
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